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Introduction: To determine whether genetic variations in CMPK1
or RRM1, which impact the pharmacodynamics of gemcitabine,
differentially affect the outcomes of non-small cell lung cancer
(NSCLC) patients treated with gemcitabine or taxane/cisplatinum.
Methods: We conducted retrospective study evaluating the associ-
ations between overall survival in 298 NSCLC patients at stages
IIIA/IIIB (140) and IV (158), treated with gemcitabine (139) or
taxane (159)/cisplatinum and 14 tagging single-nucleotide polymor-
phisms (tSNPs): 4 in CMPK1 and 10 in RRM1.
Results: The wild-type genotypes of CMPK1 IVS11057 and
IVS1928 were associated with shorter overall survival in patients
treated with the gemcitabine/cisplatinum (adjusted hazards ratio 
1.97 and 1.89; Cox pBonferroni  0.008 and 0.020), whereas this
effect was not observed in patients treated with taxane/cisplatinum.
No associations were observed for the other 2 CMPK1 or 10 RRM1
tSNPs. Analysis of the interaction between the CMPK1 and RRM1
genes showed that the survival of patients with CMPK1 IVS11057
CC and RRM1 IVS12374 TT, IVS725 AA, IVS7425 AA, or
IVS8287 TT was significantly shorter when they were treated with
the gemcitabine/cisplatinum (adjusted hazards ratio  3.00, 2.89,
3.14, and 3.00; Cox pBonferroni  0.007, 0.012, 0.006, and 0.007).
However, these effects were not observed in patients treated with
taxane/cisplatinum.
Conclusions: These findings suggest that polymorphisms of
CMPK1 and their combination with those of RRM1 are helpful in
identifying patients who will benefit less from a gemcitabine/
cisplatinum as the first-line regimen.
Key Words: CMPK1, Non-small cell lung cancer, Pharmacogenet-
ics, Platinum, RRM1.
(J Thorac Oncol. 2011;6: 1320–1329)
Lung cancer is the most common cause of cancer-relateddeath in many countries, but the survival of patients with
non-small cell lung cancer (NSCLC) has slowly been improv-
ing, and now 16% of NSCLC patients survive for 5 years.1,2
Histology does not seem to predict response/outcomes to
cytotoxic chemotherapy other than pemetrexed in NSCLC
patients.3 Despite the introduction of new drugs targeting
specific molecules, cytotoxic chemotherapy is still the main-
stay treatment for advanced NSCLC. Gemcitabine or taxane/
cisplatinum have been commonly used in the treatment of
NSCLC and have been shown to have similar treatment
efficacies in terms of response rates, overall survival, and
time to progression in phase III clinical studies.4,5 Despite
great advances in the area of pharmacogenetics, we still have
no validated biomarker with which to identify patients who
will benefit more or less from one of these two representative
chemotherapy regimens. Platinum is common to these regi-
mens. However, it is plausible that genetic variations involv-
ing the pharmacodynamics of gemcitabine and taxane can
provide clues to customized treatments because the pharma-
codynamics of the two drugs is quite different.6–8
A sequences of phosphorylations is crucial for the
metabolic activation of gemcitabine (2-deoxy-2,2-difluo-
rocytidine, dFdC): deoxycytidine kinase (DCK) generates
monophosphate (dFdCMP) and cytidine monophosphate ki-
nase 1 (CMPK1) converts it to the diphosphate form (dFd-
CDP), which is converted to the triphosphate form (dFdCTP)
by other kinases.9,10 The cytotoxicity of gemcitabine results
from dFdCDP and dFdCTP. dFdCDP is a known inhibitor of
ribonucleotide reductase 1 (RRM1), and dFdCTP competi-
tively inhibits DNA synthesis.11,12 Therefore, CMPK1 is
thought to play a major role in the activation of gemcitabine
and its cytotoxicity. To the best of our knowledge, the
polymorphisms of CMPK1 have never been examined in
cancer patients. RRM1 is involved in the production of
dinucleotides for DNA synthesis and repair and plays an
important role in determining the efficiency of gemcitabine.
Accumulating evidence indicates that the level of RRM1
expression is associated with the efficacy of gemcitabine.13–16
For these reasons, CMPK1 and RRM1 were chosen for
examination in this study, in a study population consisting of
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two groups of NSCLC patients treated with a gemcitabine or
taxane/cisplatinum.
We assessed whether tagging single-nucleotide poly-
morphisms (tSNPs) in the CMPK1 and RRM1 genes or their
interaction can be used to classify the differential overall
survival of the NSCLC patients.
PATIENTS AND METHODS
Selection of the Study Population
In this study, patients who were diagnosed with
NSCLC between March 2000 and May 2006 were selected
from our cohort. In brief, the Lung Cancer Cohort of Inha
University Hospital (Incheon, South Korea) has constructed
an extensive database that includes clinical information and
matched samples.17
All consecutive NSCLC patients with advanced stage
disease, who were treated with more than two cycles of
gemcitabine (Gemzar, Eli Lilly, Indianapolis, IN) or taxane
(Taxol, Bristol-Myers Squibb, New York, NY, or Taxot-
ere, Sanofi-Aventis, Collegeville, NJ) plus cisplatin as the
first-line treatment, were initially considered. Two hundred
ninety-eight patients who underwent full follow-up at our
hospital and whose peripheral blood lymphocytes were avail-
able for analysis were finally selected for this study. These
patients gave their written informed consent and agreed to the
aims of the study. This study was approved by the Institu-
tional Review Board of Inha University Hospital.
Tagging Polymorphisms: Selection and Genetic
Analysis
The CMPK1 gene spans approximately 44.9 kb and
contains 6 exons; the RRM1 gene spans 44.1 kb and contains
19 exons. We examined the allele frequencies of the two
genes located between nucleotide 1,100 upstream from the
start codon (ATG) and the 3 untranslated region (UTR)
using the International HapMap Project (http://www.hapmap.
org) and Japanese Single-Nucleotide Polymorphisms (http://
snp.ims.u-tokyo.ac.jp) data systems. In total, 35 polymor-
phisms (15 for CMPK1 and 25 for RRM1) showed minor
allele frequencies of more than 10% in Asian ethnic popula-
tions. From these polymorphisms, 14 tSNPs were selected
using a criterion of more than 0.9 for the value of the correlation
coefficient (r2).17 From CMPK1 and RRM1, 14 polymorphisms
were selected as tSNPs using the same criteria as in our previous
study (Table 1): for CMPK1, IVS11057 CA (rs4492666),
IVS1928 CA (rs11211524), IVS5592 CT
(rs12090346), and 1047 CT (rs1044457); and for RRM1,
756 TC (rs11030918), 269 CA (rs12806698),
IVS12374 TC (rs2284449), IVS480 GA (rs725518),
IVS725 AC (rs2044139), IVS71246 CT
(rs7940013), IVS7425 AG (rs232043), IVS8287 TC
(rs720106), Arg284Arg (rs183484), and IVS9242 TC
(rs3817657).
Genotype analyses of IVS11057 CA, IVS5592
CT, and 1047 CT for CMPK1 and 756 TC,
IVS12374 TC, IVS480 GA, IVS725 AC,
IVS71246 CT, IVS8287 TC, Arg284Arg, and
IVS9242 TC for RRM1 were performed using the Ge-TA
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nome Laboratory SNPstream Genotyping System (ultra-high
throughput), according to the manufacturer’s protocol.18 PCR
amplifications were performed in a PTC-225 Peltier Thermal
Cycler (MJ Research, Waltham, MA) using AmpliTaq Gold
DNA Polymerase. The genotypes of IVS1928 CA for
CMPK1 and 269 CA and IVS7425 AG for RRM1
were analyzed using a single-base primer extension assay
with the SNaPShot assay kit, according to the manufacturer’s
protocol (ABI, Foster City, CA). The sequences of PCR
products were analyzed by electrophoresis on an ABI
Prism 3730 DNA Analyzer. The results were analyzed
using GeneMapper software (ABI).
Statistical Methods
The 2 test for heterogeneity was used to compare the
distributions of the clinical variables and genotype frequen-
cies, and the Mann-Whitney U test was used for continuous
variables. We estimated the values of Lewontin’s coefficient,
D, and r2 with the Haploview v. 4.1 software package
(http://www.broad.mit.edu/mpg/haploview/). Associations
between genotypes or clinical variables and overall survival
were estimated using the Kaplan-Meier method and log-rank
testing for univariate analysis. The hazards ratios, adjusted
for potential confounders, and the 95% confidence intervals
were determined using the Cox proportional hazard model for
multivariate analysis. Gene-gene interactions were analyzed
with 2 test and Fisher’s exact test. All statistical testing was
done at the two-sided 0.05 level. The problem of multiple
comparisons between tSNPs was addressed using Bonferroni’s
inequality method. All analyses were performed with the SAS
software package (v. 9.1.3).
TABLE 2. Clinical Characteristics of the Patients by First-line Regimens
Variable
Total Gemcitabine/Cisplatinum Taxane/Cisplatinum
pN % N % N %
Total patients 298 100 139 46.6 159 53.4
Age
Median, yr (range) 63 64 (34 to 85) 63 (28 to 89) 0.549
Gender
Male 236 79.2 105 44.5 131 55.5 0.146
Female 62 20.8 34 54.8 28 45.2
Smoking habit
Never 59 19.8 32 54.2 27 45.8 0.192
Ever 239 80.2 107 44.8 132 55.2
ECOG performance status
0–1 222 74.5 113 50.9 109 49.1 0.126
2 69 23.2 31 44.9 38 55.1
Missing 7 2.3 1 14.3 6 85.7
Body weight loss
5% 145 48.6 65 44.8 80 55.2 0.384
5% 143 48.0 74 51.7 69 48.3
Missing 10 3.4 6 60.0 4 40.0
Histology
Squamous cell carcinoma 139 46.6 65 46.8 74 53.2 0.104
Adenocarcinoma 136 45.6 68 50.0 68 50.0
Others 23 7.7 6 26.1 17 73.9
Stage
III (IIIA/IIIB) 140 47.0 59 42.1 81 57.9 0.143
IV 158 53.0 80 50.6 78 49.4
Tumor response
CR/PR 111 37.3 51 45.9 60 54.1 0.511
SD/PD 167 56.0 81 48.5 86 51.5
Missing 20 6.7 7 35.0 13 65.0
Second-line chemotherapy
Yes 162 54.4 77 47.5 85 52.5 0.738
No 136 45.6 62 45.6 74 54.4
Radiation therapy to primary tumor 89 42 47.2 47 52.8 0.902
Median survival, mo (95% CI) 13.00 (11.35–14.65) 11.90 (9.59–14.21) 13.67 (11.36–15.97) 0.168*
Event, deaths 268 89.9 127 47.4 141 52.6
Two-sided p value by 2 test.
*Estimated by log-rank test.
ECOG, Eastern Cooperative Oncology Group; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CI: confidence interval.
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RESULTS
Study Population: Groups Treated with
Gemcitabine or Taxane/Cisplatinum
Table 2 provides the baseline characteristics of the
NSCLC patients treated with gemcitabine or taxane/cisplatinum
as the first-line regimen. One hundred fifty-nine patients (53%)
received taxane/cisplatinum, 120 (75%) of whom received the
paclitaxel and 39 (25%) of whom received the docetaxel; and
139 patients (46%) received the gemcitabine/cisplatinum.
The distributions of the clinical variables (smoking
habit, Eastern Cooperative Oncology Group [ECOG] perfor-
mance status, weight loss, histology, stage, sequential radia-
tion treatment, tumor response to chemotherapy, and second-
line chemotherapy) that might affect overall survival did not
differ across the two groups. The median survival time
(MST) of the 298 patients was 13.0 months. MST did not
differ between the two groups (log-rank p  0.168).
Tagging Polymorphisms of CMPK1 and RRM1
Three of four CMPK1 tSNPs were located in introns;
the other tSNP occurred in exon 6 (3 UTR). Seven of the 10
RRM1 tSNPs were located in introns, and 2 tSNPs were
located in the promoter region. One tSNP in exon 9 was a
synonymous polymorphism (arginine to arginine). The fre-
quencies of the wild-type alleles of CMPK1 ranged from 28
to 66% and those of RRM1 ranged from 29 to 67% (Table 3).
The distributions of the genotypes of the CMPK1 and RRM1
tSNPs did not differ between the two groups of patients (data
not shown). The linkage disequilibrium (LD) values for the 4
tSNPs of CMPK1 and the 10 tSNPs of RRM1 are shown in
Tables 4 and 5. High LDs were observed for all 14 tSNPs,
with D values of 0.8 to 1, but the r2 values were intermediate
(range, 0.05–0.95).
Association of Tagging Polymorphisms of
CMPK1 and RRM1 with Overall Survival
No associations were demonstrated between the 14
tSNPs of CMPK1 and RRM1 and the overall survival of the
298 patients. When divided into two groups, the wild-type
allele of CMPK1 IVS11057 was associated with shorter
overall survival in patients treated with the gemcitabine/
cisplatinum, but this was only marginally significant when
multiplied by 4 according to Bonferroni’s method (MST,
11.37 versus 14.17 months, log-rank pBonferroni  0.098).
After adjustment for confounding variables (body weight
loss, ECOG performance status, stage, second-line treatment,
and radiation therapy), the effect of the wild-type genotypes
of CMPK1 (IVS11057 CC and IVS1928 CC) became
more significant and were associated with shorter survival in
patients treated with the gemcitabine/cisplatinum (adjusted
hazard ratio [aHR]  1.97, 95% CI: 1.28–3.09, pBonferroni 
0.008 for CMPK1 IVS11057; aHR  1.87, 95% CI: 1.21–
2.91, pBonferroni  0.020 for CMPK1 IVS1928). These
effects were not observed in patients treated with the taxane/
cisplatinum (pBonferroni  1 for all CMPK1 tSNPs). The 10
tSNPs of RRM1 were not associated with the overall survival
of the total patients or with the overall survival of the patients
when they were divided into two groups.
Association of Combined Effect of CMPK1
IVS11057 and RRM1 with Overall Survival
Of the 135 patients treated with the gemcitabine/cis-
platinum, patients (15.6%) with the wild-type genotypes of
TABLE 4. Linkage Disequilibrium Analysis of Tagging
Single-Nucleotide Polymorphisms of CMPK1
IVS11057
(C>A)
IVS1928
(C>A)
IVS5592
(C>T)
1047
(C>T)
IVS11057 (CA) 1 1 1
IVS1928 (CA) 0.952 1 1
D
IVS5592 (CT) 0.305 0.286 1
1047 (CT) 0.314 0.297 0.052
r2
rs4492666 (IVS11057 AC) is in absolute linkage disequilibrium with
rs9436882, rs11582877, rs11211520, rs10789507, rs10890478, rs4926836, rs6660321,
rs2622925, and rs2820989; rs12090346 (IVS5592 CT) in absolute linkage with
rs7532785 and rs9436883.
TABLE 5. Linkage Disequilibrium Analysis of Tagging Single-Nucleotide Polymorphisms of RRM1
756
(T>C)
269
(C>A)
IVS12374
(T>C)
IVS480
(G>A)
IVS725
(A>C)
IVS71246
(C>T)
IVS7425
(A>G)
IVS8287
(T>C) Arg284Arg
IVS9242
(T>C)
756 (TC) 0.948 1 0.934 0.937 0.930 0.942 1 0.916 0.931
269 (CA) 0.883 1 1 1 0.991 1 1 1 0.991
IVS12374 (TC) 0.085 0.086 1 1 0.848 0.972 0.988 0.958 1
IVS480 (GA) 0.316 0.356 0.189 1 1 0.871 0.940 0.991 0.985
IVS725 (AC) 0.104 0.117 0.721 0.264 0.891 0.980 0.961 0.970 1 D
IVS71246 (CT) 0.804 0.898 0.067 0.395 0.102 1 0.844 1 0.992
IVS7425 (AG) 0.113 0.127 0.630 0.216 0.898 0.140 0.973 0.943 1
IVS8287 (TC) 0.087 0.086 0.954 0.174 0.682 0.067 0.646 0.959 1
Arg284Arg 0.229 0.270 0.127 0.744 0.186 0.297 0.191 0.132 1
IVS9242 (TC) 0.811 0.912 0.093 0.380 0.127 0.976 0.137 0.094 0.294
r2
rs725518 (IVS480 GA) is in absolute linkage with rs1662172, rs725519 and rs54816; rs10835635, (IVS725 CA) in absolute linkage with rs1348310, rs1474500,
rs2284451, rs1042919, and rs1042927; rs183484 (Arg284Arg) in absolute linkage with rs2735691, rs232054, rs1980412, and rs2735689; rs3817657 (IVS9242 TC) in absolute
linkage with rs2268168, rs2056853, and rs10835611.
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CMPK1 IVS11057 and RRM1 IVS7425 survived for
significantly shorter periods than did the other patients
(84.4%) when multiplied by 14 as the number of genes used
for multiple comparison, according to Bonferroni’s method
(MST, 9.27 versus 14.17 months, pBonferroni 0.008; Table 6;
Figure 1). Significant associations with overall survival were
also observed in the gene-gene interaction analysis of
CMPK1 IVS11057 and RRM1 IVS12374, IVS725, or
IVS8287. After adjustment for confounding variables, the
patients with the wild-type genotypes of CMPK1 IVS11057
and RRM1 IVS7425 had a significantly increased risk of
death compared with that of the other patients (aHR  3.14,
95% CI: 1.86–5.29, pBonferroni  0.007; Table 7). However,
these gene-gene interaction effects on overall survival were
not observed in patients treated with the taxane/cisplatinum
(pBonferroni  1 for all interactions between CMPK1 and
RRM1).
DISCUSSION
In this study, we demonstrated that the polymorphism
at CMPK1 IVS11057 and its interaction with RRM1 had
different prognostic effect in patients with advanced NSCLC
treated with gemcitabine or taxane/cisplatinum. These find-
ings can provide pivotal clinical information for patient
treatment assignments.
In this study, we selected taxane/cisplatinum as nega-
tive control because there are no data to suggest that CMPK1
and RRM1 have a role in the transport, activation, or mech-
anism of action of taxanes. In a report by Bepler et al.,14 the
expression of RRM1 in lung cancer cell lines was a more
important determinant of gemcitabine efficiency than of plat-
inum efficiency (in vitro 50% inhibitory concentration: 100-
fold versus 2-fold, respectively). This supports the concept
that genes involved in gemcitabine metabolism are good
candidates for differential prognostic markers of the efficacy
of gemcitabine and taxane/cisplatinum. Therefore, in this
study, we examined a sample population consisting of two
groups of NSCLC patients from our lung cancer cohort.
Although CMPK1 is known to play a crucial role in the
activation of gemcitabine and in its cytotoxicity, the prog-
nostic potential of its polymorphisms has never been exam-
ined. Kocabas et al.10 found three nonsynonymous SNPs (144
GT, 233 GA, and 248 AC) in samples obtained from
the general population, but their functional analysis of these
SNPs showed modest changes in the protein level or allo-
zyme activity for only 248 AC. We did not include these
SNPs in the tSNPs examined in this study because the
frequencies of these variant alleles were expected to be less
than 10% in Asian ethnic groups (6.7% for 144 GT, 1.5%
for 233 GA, and 0.8% for 245 AC).
Most previous studies investigating the association of
RRM1 polymorphisms with overall survival in patients
treated with a gemcitabine combination have focused on two
genetic variations in the promoter region (756 TC and
269 CA).19–21 Similar to the results of these studies, our
results also showed no significant association between these
two SNPs or eight other tSNPs and overall survival (Table 3).
In this study, we found that of the four tSNPs of
CMPK1, IVS11057, and IVS1928 showed a significant
association with the overall survival of only those patients
treated with the gemcitabine/cisplatinum (pBonferroni 
0.008 and 0.020, respectively) after adjustments were made
for body weight loss, ECOG performance status, stage, sec-
ond-line treatment, and radiation therapy. Gene-gene interac-
tion analysis was used in an attempt to generate a more robust
model because trends toward shorter survival in the wild-type
genotypes were observed for most tSNPs of CMPK1 and
RRM1, although they were not statistically significant. The
wild-type alleles of both CMPK1 and RRM1 (CMPK1
IVS11057 CC and RRM1 IVS12374 TT, IVS725 AA,
IVS7425 AA, and IVS8287 TT) carried a higher risk of
death in patients treated with the gemcitabine/cisplatinum
(aHR: 2.89–3.14), but they had no effect on the risk of death
in patients treated with taxane/cisplatinum (aHR: 1.00–1.11;
Table 7).
The interactions between CMPK1 and RRM1, as well
as the functions of their individual tSNPs, are still unclear.
However, the diphosphate form of gemcitabine is known to
act as an inhibitor of RRM1, which causes a reduction in the
deoxynucleoside triphosphate pools, which are important in
DNA repair and synthesis.22 Therefore, we hypothesize that
the wild-type allele of CMPK1 IVS11057 may be associ-
ated with the reduced expression or activity of CMPK1,
resulting in less of the diphosphate form of gemcitabine,
which inhibits RRM1 function.
This study has several limitations. First, a retrospective
study by its very nature has some limitations. However, all
298 patients were treated at a single institution, and the
clinical information, including a thorough follow-up and
survival measurements, were obtained prospectively. The
size of this study sample was large enough for this kind of
study. This study was conducted before approval of pem-
etrexed in South Korea, so there was no issue with a histology
bias as well. Moreover, we used strict criteria to define the
level of statistical significance, and we used Bonferroni’s
method to address the problems caused by multiple compar-
isons between tSNPs. We believe that these procedures can
reduce the bias or type I error attributable to possible con-
founding factors. Second, the fact that the stratum of the
holding risk allele(s) decreased from 29.9% for CMPK1
IVS11057 to 16.3–19.8% for its combination with the four
tSNPs of RRM1 is a weak point in the application of the two
genes’ genotypes to treatment assignment. Third, the question
of whether genetic variation at CMPK1 IVS11057 or its
interaction with four tSNPs of RRM1 affects the functions of
each gene-encoded protein and their interactions is still un-
clear and must be determined in a future study. The mRNA
expression of CMPK1 and RRM1 should also be considered
in the next study, although prognostic markers recently de-
veloped based on mRNA have significant limitations in terms
of their general applicability. It is not easy to obtain enough
tissue from advanced NSCLC patients. Good facilities, such
as laser capture microdissection apparatus and clinical labo-
ratories for gene expression analysis, are mandatory for the
successful application of this type of analysis.
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In conclusion, these findings suggest that the polymor-
phism of CMPK1 IVS11057 or its combination with four
RRM1 tSNPs should be helpful in identifying NSCLC pa-
tients who will not benefit from treatment with the gemcit-
abine/cisplatinum, so an alternative treatment option can be
considered as the first-line regimen for these patients. How-
ever, the results from this study, although promising, require
confirmation in the prospective setting.
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